As ERAP1 downregulation has been shown to be a significant predictor of decreased survival in cervical carcinoma, insight into the possible underlying mechanisms of this downregulation may yield novel targets for the designs of antitumor immunotherapies. This evidence concerns the gene ERAP1 and cervical carcinoma.